ArticleIndian journal of dermatology
Dysregulation of T Helper 17 Cell Pathway In Vitiligo.
Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulation of the T helper 17 (Th17) cell pathway can result in autoimmune activation and chronic inflammation. Vitiligo is an autoimmune disorder characterised by melanocyte cytotoxicity. The aim of this study was to examine the role of the Th17 pathway in the pathogenesis of vitiligo. The three components of the pathway were evaluated using plasma interleukin (IL6), IL23, and IL10 for the modulatory component, Method: The study was carried out using a case-control design. The case group comprised patients diagnosed with vitiligo ( Results: In vitiligo patients, IL6 was 2.3 times higher ( Conclusions: Together, these results indicate that the Th17 pathway is likely to be overactive in vitiligo due to dysregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.